Skip to content
lifestyle.hubspotes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oculis Holding AG
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
October 29, 2026
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
October 22, 2026
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
October 20, 2026
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
October 19, 2026
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
October 7, 2026
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
October 1, 2026
Oculis Announces Resignation of Lionel Carnot from Board of Directors
September 30, 2026
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
August 24, 2026
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
August 10, 2026
Oculis Reports Q2 2026 Financial Results and Provides Company Update
August 6, 2026
1
2
Next Page
→